

Appendix B. Top-Selling Drugs

Table B-1. Top 15 Best-Selling Drugs of 2018

Biologics in bold; dollars in billions

Brand Name	Nonproprietary Name	Sponsor Companies	2018 Sales
Humira	adalimumab	AbbVie	\$19.936
Eliquis	apixaban	Bristol-Myers Squibb and Pfizer	\$9.872
Revlimid	lenalidomide	Celgene	\$9.685
Opdivo	nivolumab	Bristol-Myers Squibb and Ono Pharmaceutical	\$7.570
Keytruda	pembrolizumab	Merck	\$7.171
Enbrel	etanercept	Amgen and Pfizer	\$7.126
Herceptin	trastuzumab	Roche (Genentech)	\$6.981
Avastin	bevacizumab	Roche (Genentech)	\$6.847
Rituxan	rituximab	Roche (Genentech) and Biogen	\$6.750
Xarelto	rivaroxaban	Bayer and Johnson & Johnson	\$6.589
Eylea	afibercept	Bayer and Regeneron Pharmaceuticals	\$6.551
Remicade	infliximab	Johnson & Johnson and Merck & Co.	\$5.908
Pevnar 13	pneumococcal vaccine	Pfizer	\$5.802
Stelara	ustekinumab	Janssen Biotech (Johnson & Johnson)	\$5.156
Lyrica	pregabalin	Pfizer	\$4.970

Source: Genetic Engineering & Biotechnology News, March 11, 2019.

Notes: Genetic Engineering & Biotechnology News indicate in the Notes for this article that the above amounts include U.S. sales and, where applicable, sales elsewhere in the world. According to the text of the article, the “drugs are ranked based on sales or revenue reported for 2018 by biopharma companies in press announcements, annual reports, investor materials, and/or conference calls.”

Author Information

Agata Dabrowska
Analyst in Health Policy

Acknowledgments

Judith Johnson, retired CRS Specialist in Biomedical Policy, had authored previous versions of this report.